Considerations In Response to Drug-Drug Interaction Guidances

Check out the recent IQ consortium publication: Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on Down-regulation, CYP2C Induction and CYP2B6 Positive Control, which was published in Drug Metabolism and Disposition and included data generated at XenoTech utilizing our attaching human hepatocytes…

Learn more about:

Primary Human Hepatocytes Drug-Drug Interaction Regulatory Guidance

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing XenoTech’s scientific expertise and knowledge with scientists around the world.

Considerations In Response to Drug-Drug Interaction Guidances

Learn more about:

About the Authors

Subscribe to our Newsletter

Do you have a question or a request for upcoming blog content?

Considerations In Response to Drug-Drug Interaction Guidances

Learn more about:

Share Post

About the Authors

Related Posts

ADME and Drug-Drug Interactions for the Toxicologist

FDA Guidance: Many In Vitro DDI Evaluations Should Precede FIH Studies

Considerations In Response to Drug-Drug Interaction Guidances

Subscribe to our Newsletter

Do you have a question or a request for upcoming blog content?